Navigation Links
Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
Date:10/29/2008

Technology Intended To Reduce Failure Rates Of In Vitro Fertilization and

Intrauterine Insemination Procedures

LA JOLLA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) announced today that it has entered into a series of agreements to acquire exclusive worldwide rights from several inventors to develop and commercialize technologies relating to the use of adenosine 5'-triphosphate (ATP) to improve motility of human and animal sperm. ATPotent is a novel ATP-based sperm processing medium designed to reduce failure rates of in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures.

Male factor infertility is implicated in about half of the six million infertile couples in the US. Lack of, or low sperm motility or movement, also known as asthenozoospermia, is a common cause of human male infertility. It has been reported in the medical literature that the prevalence of asthenozoospermia in infertile men is approximately 82 percent. Currently, there is no FDA-approved product that enhances sperm motility.

Duska's sponsored studies at the University of Pennsylvania and the University of Padua (Italy) have shown that ATP treatment of poorly motile human sperm in vitro (outside of the human body) resulted in improved motility parameters and increased frequency of hyperactivated sperm. The improved motility parameters were also observed in human sperm derived from males with asthenozoospermia and in thawed cryopreserved human sperm.

Results from these recent studies support earlier observations from a non-Duska sponsored European study in which increased success rate of IVF procedures were observed when ATP-treated sperm derived from infertile males with asthenozoospermia were used.

"Today's announcement underscores Duska's commitment to develop novel targeted therapies utilizing ATP," said Amir Pelleg, PhD, Duska's President and Chief Scientific Officer. "We believe that the newly acquired proprietary technology substantially strengthens the value of our ATPotent program and will allow us to address a pressing medical need in artificial reproductive technologies."

About Duska Therapeutics

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska's ATPace is expected to enter a pivotal Phase 3 clinical trial, Duska's CDP-1050 is expected to commence a Phase 2 clinical trial, the belief that the newly acquired proprietary technology substantially strengthens the value of our ATPotent program and will allow us to address a pressing medical need in artificial reproductive technologies. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful and that the newly acquired proprietary technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP to improve motility of sperm. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
2. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
3. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... Carefree, AZ (PRWEB) , ... February 10, 2016 , ... ... coach in new book , Pioneering book "Better with Age: The Ultimate Guide to ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, will ... night, Feb. 8, prior to the evening session of the university’s 80th Annual Bible ... Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, will ...
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016  The ALS Association, in partnership with ALS Finding ... generate a biomarker to track TDP43 aggregation. The successful team(s) ... $1 million investment. --> ... nerve cells in the brain and the spinal cord. Eventually, ... muscle movement, which often leads to total paralysis and death ...
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... 2016 Antibacterial Drugs Market - Global ... 2023 ", reveals that the global antibacterial drugs market is ... 2023 owing to patent expiries of blockbuster drugs. Even though ... the forecast period, the value is anticipated to decline from ... --> Antibacterial Drugs Market - Global Industry Analysis, Size, ...
Breaking Medicine Technology: